The advent of LipiView Diagnostics for quantifying the amount of natural oil present in the protective watery layer of your eyes, and the LipiFlow thermal treatment technology, was no doubt exciting, but it was not until 2008 that the winds of change began to blow. The pioneering efforts of many researchers around the world and the pragmatic contributions of TearScience were instrumental in changing the views of an entire industry that was 95% focused on Dry Eye being Lacrimal or tear-based. An ocular revelation occurred: “95%” was about to become “86%”. What do we mean?
The 95% of eye care professionals and patients with Dry Eye believed their condition was tear based when in fact over 86% of all Dry Eye cases are oil based and ultimately, Meibomian Gland Dysfunction (MGD).
In 2011, international Meibomian Gland Workshop brought research to the forefront that proclaimed the complete opposite of the story that had been told for decades prior. The MGD Workshop report stated that MGD ‘may well be the leading cause of dry eye throughout the world’ and a follow up study showed that over 86% of all dry eye cases are Evaporative Dry Eye (EDE). Today EDE is accepted as the most common form of dry eye. While EDE is a chronic and progressive disease, it can be managed in most cases by treating its root cause, which is the blockage of the Meibomian Glands that naturally occurs with age or as a result of environmental impact, medication, evaporative stress and even contact lens wear.
Many in the industry are now beginning to learn and understand Meibomian Gland Dysfunction (MGD) or the blockage of oil production in the Meibomian Glands as the root cause of Dry Eye. As many begin to embrace MGD, LipiView and LipiFlow technology is contributing to a dramatic shift how we approach Dry Eye treatment. That’s good news for millions of those who suffer from Dry Eye.
The story of Tear Science and its MGD treatment technology to treat the root cause of Dry Eye is a compelling story that millions across the world need to know. In previous years, the only answer to dry eye was prescription medications, warm compresses, drops, lid scrubs and punctual plugs. “There is no doubt these treatments are still relevant, but the reliance on many of them will soon be behind us due to the innovation from Tear Science and its groundbreaking Dry Eye diagnostic and treatment technology” according Alan Glazier, a prominent OD and one of the first practices to employ the use of LipiFlow in the United States.
If you suffer from Dry Eye, the research and innovation by Tear Science is a dramatic revelation for millions, especially since there is now a proven, FDA cleared treatment that could help over 86% of the dry eye population. If you have Dry Eye, there is a good chance you are the 86% and we encourage you to seek out an optometrist or ophthalmologist who understands MGD and who has embraced the newest treatment, Lipiflow.
For more information on Tear Science, the LipiFlow treatment system, Meibomian Gland Dysfunction (MGD) or dry eye, visit dryeyeandmgd.com.